Axogen, Inc. AXGN
Updated: 16 Jun 2026
No signal published yet
We already track Axogen and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Axogen, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Axogen free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On April 28, 2026, Axogen reported first-quarter revenue of $61.5 million and raised its full-year 2026 revenue guidance to at least $270 million. This growth follows the FDA's December 2025 BLA approval for the Avance Nerve Graft, a key milestone for the company's biologic platform. As of June 2026, Axogen's market capitalization reached approximately $2.3 billion.
What Firelda Watch includes for Axogen, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Axogen, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Axogen free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more